• Vaccine Name: ARM
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: ARM fusion protein composed of Ag85B, Rv2660c, and MPT70 from Mycobacterium tuberculosis (Hu et al., 2025).
• Ag85B from M. tuberculosis H37Rv gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Hu et al., 2025).
  • Detailed Gene Information: Click Here.
• Rv2660c gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Hu et al., 2025).
  • Detailed Gene Information: Click Here.
• mpt70 gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation (Hu et al., 2025).
  • Detailed Gene Information: Click Here.
• Adjuvant: CpG oligodeoxynucleotide 1826 (CAF10) vaccine adjuvant
  • Adjuvant name: CpG oligodeoxynucleotide 1826 (CAF10) vaccine adjuvant
  • VO adjuvant ID: VO_0005579
  • Description: CpG oligodeoxynucleotide 1826 was used as the vaccine adjuvant to enhance Th1-biased immune responses in ARM vaccine (Hu et al., 2025).
• Preparation: The ARM fusion protein was recombinantly expressed and purified, then dissolved in phosphate-buffered saline (PBS) and mixed with CpG ODN 1826 prior to intramuscular immunization (Hu et al., 2025).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: C57BL/6
• Host gender: female
• Vaccination Protocol: Mice were intravenously infected with Mycobacterium tuberculosis H37Ra and, four weeks post-infection, were immunized intramuscularly with the ARM fusion protein formulated in PBS with CpG ODN 1826. A booster immunization was administered two weeks later, and immune responses and bacterial loads were evaluated at multiple time points post-treatment (Hu et al., 2025).
• Challenge Protocol: Mice were challenged by intravenous infection with Mycobacterium tuberculosis strain H37Ra prior to vaccination to establish a post-exposure therapeutic model (Hu et al., 2025).
• Efficacy: ARM vaccination significantly reduced bacterial loads in the lungs and spleen, improved body weight recovery, and alleviated pulmonary pathology compared to PBS-treated controls and BCG-vaccinated mice (Hu et al., 2025).
• Description: ARM is a tuberculosis fusion protein vaccine composed of Ag85B, Rv2660c, and MPT70, evaluated as a therapeutic subunit vaccine in a post-exposure mouse model. The vaccine enhances both cellular and antibody-mediated immunity, leading to improved control of Mycobacterium tuberculosis infection and reduced disease pathology (Hu et al., 2025).
• Information about this animal model: Mouse Model for TB research